Ulcerative Colitis

Regardless of immunosuppression medication status, most patients with inflammatory bowel disease mounted a high-positive antibody response to the standard SARS-CoV-2 vaccination regimen, according to research.

In this Healio video series, which focuses on cultural competency in the treatment of inflammatory bowel disease, Neha D. Shah, MPH, RD, CNSC, CHES, discusses the food culture in South Asia and the associated challenges when treating IBD.

Immunogenicity of the COVID-19 vaccine varied in patients with inflammatory bowel disease based on immunosuppressive drug therapy, according to research published in The Lancet Gastroenterology and Hepatology.

Healio presents the following collection of stories from Crohn’s and Colitis Congress 2022. Topics include the effectiveness of intestinal ultrasound, cultural barriers in inflammatory bowel disease care, therapeutics coming down the IBD pipeline and more.

Results from a new survey published in Inflammatory Bowel Diseases highlight the need for improved communication between physicians and patients regarding IBD treatment goals and expectations.

Malnutrition was found to be highly prevalent in patients with inflammatory bowel disease and was also found to be associated with adverse sociopsychological status, according to data published in Inflammatory Bowel Disease.

In a Healio exclusive video, Tina Aswani Omprakash, a presenter at the Crohn’s and Colitis Congress, shares her experience with cultural competency as it relates to mental health and surgery for inflammatory bowel disease.

The simplified endoscopic mucosal assessment of Crohn’s disease is highly effective in evaluating endoscopic improvement in patients, according to results presented at the Crohn’s and Colitis Congress.

Patients with ulcerative colitis were more likely to respond to therapy if started on Entyvio within 30 days of diagnosis rather than if delayed by other initial treatments, according to a presenter at the Crohn’s and Colitis Congress.

Mirikizumab correlated with a greater reduction in disease severity among patients with ulcerative colitis and moderate to severe Crohn’s disease, according to a poster presentation at the Crohn’s and Colitis Congress.